Isturisa FDA Approval History
Isturisa (osilodrostat) is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing’s disease.
Development Timeline for Isturisa
|Mar 8, 2020||Approval FDA Approves Isturisa (osilodrostat) for the Treatment of Cushing’s Disease|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.